Friday, May 27 2022

NEW YORK, May 7, 2022 /PRNewswire/ —

WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) Between June 10, 2019 and February 182022, inclusive (the “Class Period”), of the significant May 24, 2022 lead applicant deadline.

SO WHAT: If you purchased Homology securities during the Class Period, you may be entitled to compensation without payment of fees or out-of-pocket costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for more information on the class action. A class action lawsuit has already been filed. If you wish to act as lead plaintiff, you must move the Court not later than May 24, 2022. A lead plaintiff is a representative party acting on behalf of other class members to direct litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified attorneys with proven track records in leadership roles. Often, companies issuing reviews do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually handle securities class action lawsuits, but are merely middlemen who refer clients or partner with law firms that actually litigate the cases. Be wise in choosing lawyers. Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation. Rosen Law Firm has reached the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has ranked in the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company obtained more than $438 million for investors. In 2020, founding partner Laurence Rosen has been named by law360 as a Titan of the Plaintiffs Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the defendants throughout the class action period made false and/or misleading statements and/or failed to disclose that: (1) the homology overstated the efficacy and risk mitigation regarding HMI-102, which is in a phase I/II clinical phase pheNIX trial and a gene therapy for the treatment of phenylketonuria (PKU) in adults; (2) as a result, it was unlikely that Homology would be able to market HMI-102 in its current form; and (3) as a result, the defendants’ public statements were materially false and misleading at all relevant times. When the real details entered the market, the lawsuit claims investors suffered damages.

To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for more information on the class action.

No class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent party member and do nothing at this point. An investor’s ability to participate in any potential future recovery does not depend on their status as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firmon Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

SOURCE Rosen Law Firm, Pennsylvania

Previous

Betmotion launches new website powered by Salsa technology

Next

Is your wealth advisor independent? Sometimes it's not easy to say

Check Also